1) Hosoya K, et al : Advances in the cell biology of transport via the inner blood-retinal barrier : establishment of cell lines and transport functions. Biol Pharm Bull 28 : 1-8, 2005
2) Bennett NH, et al : Material, immunological, and practical perspectives on eye drop formulation. Adv Funct Mater 30 : 1908476, 2020
3) 新家眞 : 点眼薬の吸収と動態 (眼内移行, 流出など). 眼科診療プラクティス 11. 眼科治療薬ガイド, 本田孔士編, 文光堂, 東京, 387-392, 1994
4) 河嶋洋一 : 点眼薬の剤形と特徴. 「1滴」のチカラを科学する! 点眼剤. Rp.+, 南山堂, 17 : 21-25, 2018
5) Garcia-Quintanilla L, et al : Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration. Pharmaceutics 11 : 365, 2019
6) Stewart MW : Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol 7 : 167-180, 2014
7) Zhu Q, et al : Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115 : 1750-1755, 2008
8) Fauser S, et al : Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol 158 : 532-536, 2014
9) Edington M, et al : Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. Expert Opin Drug Metab Toxicol 13 : 1217-1224, 2017
10) Nan K, et al : Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol 94 : 654-658, 2010
11) Kovacs K, et al : Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon's injection. Am J Ophthalmol 153 : 939-948, 2012
12) Weijtens O, et al : High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol 128 : 192-197, 1999